New Two-Drug attack on tough blood cancers
NCT ID NCT05038592
Summary
This study is testing a two-drug combination for adults with certain advanced blood cancers, including chronic myelomonocytic leukemia (CMML). The goal is to find the safest and most effective dose of a targeted drug (tagraxofusp) that delivers a toxin directly to cancer cells, combined with a standard chemotherapy drug (decitabine). Researchers want to see if this combination can help control the disease in patients who have not responded well to other treatments or are newly diagnosed with higher-risk disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC MYELOMONOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.